Clinical Therapeutics, 0149-2918


More filtering options
  1. 2019
  2. Benefit–risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis

    Patrick Vermersch, Vittorio Martinelli, Claudia Pfleger, Peter Rieckmann, Lucia Alonso-Magdalena, Andrew Galazka, Fernando Dangond & Lawrence Phillips, 2019 Jan 1, (Accepted/In press) In : Clinical Therapeutics.

    Research output: Contribution to journalArticle

  3. 2012
  4. Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model

    Asa By, Patrik Sobocki, Arne Forsgren & Sven-Arne Silfverdal, 2012, In : Clinical Therapeutics. 34, 1, p. 177-189

    Research output: Contribution to journalArticle

  5. 2008
  6. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.

    Ola Ghatnekar, Thor Alvegård, Nils Conradi, Stig Lenhoff, Ulf-Henrik Mellqvist, Ulf Persson & Mickael Löthgren, 2008, In : Clinical Therapeutics. 30, 9, p. 1704-1713

    Research output: Contribution to journalArticle

  7. 2006
  8. 2003
  9. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The treat-to-target (3T) study

    Anders G Olsson, Mats Eriksson, Owe Johnson, Thomas Kjellstrom, Jan Lanke, Mogens Lytken Larsen, Terje Pedersen, Matti J Tikkanen & Olov Wiklund, 2003, In : Clinical Therapeutics. 25, 1, p. 119-138

    Research output: Contribution to journalArticle

  10. 1996
  11. Intravenous immunoglobulin and hepatitis C virus: the Scandinavian experience

    Janne Björkander, Anders Fasth & Anders Widell, 1996, In : Clinical Therapeutics. 18, Suppl 2, p. 73-82

    Research output: Contribution to journalArticle